The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms
NCT00002357 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144
Last updated 2005-06-24
Summary
To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone.
PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.
Conditions
- HIV Infections
Interventions
- DRUG
-
HBY 097
- DRUG
-
Zidovudine
Sponsors & Collaborators
-
Hoechst Marion Roussel
lead INDUSTRY
Study Design
- Purpose
- TREATMENT
- Masking
- DOUBLE
Eligibility
- Min Age
- 13 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection
NCT00002290 ·Status: COMPLETED ·Phase: NA
-
The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children
NCT00000967 ·Status: COMPLETED ·Phase: PHASE1
-
A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past
NCT00002320 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients
NCT00002326 ·Status: COMPLETED ·Phase: PHASE1
-
The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)
NCT00002048 ·Status: COMPLETED ·Phase: NA
-
The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection
NCT00002347 ·Status: COMPLETED ·Phase: PHASE2
-
A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell
NCT00002323 ·Status: COMPLETED ·Phase: NA
-
Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-naïve HIV-infected Patients
NCT01540240 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART
NCT06430905 ·Status: TERMINATED ·Phase: PHASE1
-
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
NCT00002324 ·Status: COMPLETED ·Phase: PHASE2
-
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
NCT00001119 ·Status: COMPLETED ·Phase: NA
-
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)
NCT00002014 ·Status: COMPLETED ·Phase: PHASE1
-
The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT
NCT00002436 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children
NCT00000637 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients
NCT00000699 ·Status: COMPLETED ·Phase: PHASE1
-
A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC
NCT00002155 ·Status: COMPLETED ·Phase: NA
-
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3
NCT00002124 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients
NCT00001010 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)
NCT00000649 ·Status: COMPLETED ·Phase: PHASE1
-
Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3
NCT00001993 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)
NCT00002079 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease
NCT00001045 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.
NCT00002199 ·Status: COMPLETED ·Phase: PHASE3
-
A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine
NCT00000628 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV
NCT00000791 ·Status: COMPLETED ·Phase: PHASE2